NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
36M of 34M shares
Institutional holders
239
75 new, 40 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $2.43M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander | 932,863 | 5.40% | 13G (passive) | Jun 27, 2025 |
| Daniel Mack | 709,761 | 5.72% | 13G (passive) | Jun 30, 2025 |
| Abigail P. Johnson | 4,303,188 | 15.00% | 13G (passive) amendment | Mar 31, 2026 |
| Sina Toussi | 3,345,978 | 9.80% | 13G (passive) amendment | Sep 25, 2026 |
| Two Seas Capital LP | 3,092,234 | 9.10% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC | 3,036,761 | 11.10% | 13G (passive) | Feb 27, 2026 |
| BlackRock, Inc. | 2,643,796 | 7.80% | 13G (passive) | Jun 30, 2026 |
| Lampert Mark N | 2,391,075 | 7.10% | 13G (passive) amendment | Jun 30, 2026 |
| Two Seas Capital GP LLC | 1,959,178 | 6.80% | 13G (passive) | Mar 31, 2026 |
| Chen Yu | 1,933,333 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 1,747,653 | 5.17% | 13G (passive) | Jun 30, 2026 |
| Bvf Inc/Il | 1,276,595 | 7.40% | 13G (passive) | Jul 1, 2025 |
| Susquehanna Securities, LLC | 1,235,864 | 6.30% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NKTR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 5,067,920 | 14.84% | $353.79M | +764,732 | 0.02% |
| Two Seas Capital LP | 3,092,234 | 9.06% | $215.87M | +1,133,056 | 4.28% |
| BlackRock, Inc. | 2,941,851 | 8.62% | $205.37M | +2,249,201 | 0.00% |
| Bvf Inc/Il | 2,391,075 | 7.00% | $166.92M | −168,520 | 4.27% |
| Vanguard Capital Management LLC | 1,496,849 | 4.38% | $104.50M | +299,794 | 0.00% |
| Two Sigma Investments, LP | 1,202,004 | 3.52% | $83.91M | +271,263 | 0.06% |
| Vestal Point Capital, LP | 1,000,000 | 2.93% | $69.81M | +715,000 | 1.63% |
| Morgan Stanley | 936,560 | 2.74% | $65.38M | +277,173 | 0.00% |
| State Street Corp | 909,679 | 2.66% | $63.50M | +664,952 | 0.00% |
| Geode Capital Management, LLC | 881,306 | 2.58% | $61.54M | +534,511 | 0.00% |
| Prosight Management, LP | 810,000 | 2.37% | $56.55M | +75,000 | 9.74% |
| Armistice Capital, LLC | 724,000 | 2.12% | $50.54M | +146,000 | 0.62% |
| Gilder Gagnon Howe & Co LLC | 600,873 | 1.76% | $41.95M | +329,115 | 0.43% |
| Millennium Management LLC | 478,120 | 1.40% | $33.38M | +73,843 | 0.01% |
| Braidwell LP | 473,617 | 1.39% | $33.06M | +250,916 | 1.22% |
| Sofinnova Investments, Inc. | 471,763 | 1.38% | $32.93M | −37,783 | 1.70% |
| Woodline Partners LP | 470,875 | 1.38% | $32.87M | +55,540 | 0.10% |
| Orbimed Advisors LLC | 465,346 | 1.36% | $32.49M | +190,346 | 0.60% |
| UBS Group AG | 428,400 | 1.25% | $29.91M | +108,228 | 0.00% |
| Emerald Advisers, LLC | 390,158 | 1.14% | $27.24M | −4,446 | 0.64% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 239 | 36M | 100.0% | 75 / 100 | 41 / 40 | 13M | 3M |
| Q1 2026 | 207 | 27M | 78.2% | 69 / 73 | 46 / 30 | 14M | 3M |
| Q4 2025 | 172 | 17M | 50.7% | 61 / 48 | 42 / 31 | 7M | 4M |
| Q3 2025 | 145 | 14M | 42.2% | 64 / 41 | 26 / 19 | 9M | 3M |
| Q2 2025 | 101 | 8M | 22.4% | 101 / 0 | 0 / 0 | 8M | 0M |
| Q2 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2021 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NKTR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,834,001 | 5.37% | $118.99M | 0.12% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,075,108 | 3.15% | $75.05M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 896,117 | 2.62% | $62.56M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 492,779 | 1.44% | $31.97M | 0.12% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 419,823 | 1.23% | $27.24M | 0.11% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 387,571 | 1.14% | $27.06M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 376,892 | 1.10% | $26.63M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 285,292 | 0.84% | $19.92M | 0.13% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 172,419 | 0.50% | $12.18M | 0.16% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 162,987 | 0.48% | $10.57M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 151,830 | 0.44% | $9.85M | 0.04% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 115,142 | 0.34% | $8.04M | 1.88% | Jun 30, 2026 |
| Emerald Growth Fund | 104,721 | 0.31% | $7.40M | 0.50% | Jul 31, 2026 |
| Emerald Growth Fund | 104,721 | 0.31% | $8.91M | 0.63% | Apr 30, 2026 |
| SmallCap Growth Fund I | 92,975 | 0.27% | $6.57M | 0.26% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Howard W. Robin | President & CEO, Director | 54,655 | 0.16% | Aug 20, 2026 |
| Jonathan Zalevsky | Chief R&D Officer | 9,570 | 0.03% | Aug 20, 2026 |
| Linda M. Rubinstein | Interim CFO | – | – | May 26, 2026 |
| Mark Andrew Wilson | Chief Legal Officer | 21,585 | 0.06% | Nov 25, 2025 |
| Roy A. Whitfield | Director | 21,185 | 0.06% | Sep 25, 2026 |
| Robert Chess | Director | 19,299 | 0.06% | Sep 25, 2026 |
| Diana Brainard | Director | 3,904 | 0.01% | Sep 25, 2026 |
| Jeffrey Robert Ajer | Director | 4,277 | 0.01% | Sep 25, 2026 |
| R. Scott Greer | Director | 22,239 | 0.07% | Sep 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Chess Director | Sep 23, 2026 | Award | +2,000 | – | – | 19,019 |
| R. Scott Greer Director | Sep 23, 2026 | Award | +2,000 | – | – | 22,239 |
| Jeffrey Robert Ajer Director | Sep 23, 2026 | Award | +2,000 | – | – | 4,277 |
| Diana Brainard Director | Sep 23, 2026 | Award | +2,000 | – | – | 3,904 |
| Roy A. Whitfield Director | Sep 23, 2026 | Award | +2,000 | – | – | 16,417 |
| Jonathan Zalevsky Chief R&D Officer | Aug 18, 2026 | Sale | −186 | $71.98 | $13.39K | 9,570 |
| Howard W. Robin President & CEO, Director | Aug 18, 2026 | Sale | −418 | $71.98 | $30.09K | 54,627 |
| Jonathan Zalevsky Chief R&D Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −5,681 | $70.00 | $397.67K | 9,756 |
| Howard W. Robin President & CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −4,500 | $61.65 | $277.43K | 55,045 |
| Howard W. Robin President & CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,500 | $60.81 | $334.46K | 59,545 |
| Howard W. Robin President & CEO, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −4,697 | $60.71 | $285.15K | 65,045 |
| Howard W. Robin President & CEO, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −5,303 | $59.97 | $318.02K | 69,742 |
| Jonathan Zalevsky Chief R&D Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −5,538 | $60.71 | $336.21K | 15,437 |
| Jonathan Zalevsky Chief R&D Officer | May 19, 2026 | Sale | −199 | $65.51 | $13.04K | 20,975 |
| Howard W. Robin President & CEO, Director | May 19, 2026 | Sale | −444 | $65.51 | $29.09K | 75,045 |
| Jonathan Zalevsky Chief R&D Officer | Feb 18, 2026 | Sale | −180 | $73.00 | $13.14K | 21,174 |
| Howard W. Robin President & CEO, Director | Feb 18, 2026 | Sale | −423 | $73.00 | $30.88K | 75,489 |
| Jonathan Zalevsky Chief R&D Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −3,867 | $35.67 | $137.94K | 21,354 |
| Jonathan Zalevsky Chief R&D Officer | Dec 22, 2025 | Award | +6,250 | – | – | 25,221 |
| Howard W. Robin President & CEO, Director | Dec 22, 2025 | Award | +21,667 | – | – | 75,912 |
| Jonathan Zalevsky Chief R&D Officer | Nov 25, 2025 | Sale | −1,157 | $54.28 | $62.80K | 18,971 |
| Howard W. Robin President & CEO, Director | Nov 25, 2025 | Sale | −2,207 | $54.28 | $119.80K | 54,245 |
| Mark Andrew Wilson Chief Legal Officer | Nov 25, 2025 | Sale | −630 | $54.28 | $34.20K | 21,585 |
| Jonathan Zalevsky Chief R&D Officer | Nov 21, 2025 | Award | +2,666 | – | – | 20,128 |
| Howard W. Robin President & CEO, Director | Nov 21, 2025 | Award | +7,110 | – | – | 56,452 |
| Mark Andrew Wilson Chief Legal Officer | Nov 21, 2025 | Award | +1,903 | – | – | 22,215 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −1,210 | $48.18 | $58.30K | 49,342 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −2,156 | $47.49 | $102.39K | 50,552 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −1,200 | $46.41 | $55.69K | 52,708 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −2,100 | $45.16 | $94.84K | 53,908 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −1,136 | $39.89 | $45.32K | 56,008 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −2,226 | $38.82 | $86.41K | 57,144 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −3,304 | $37.87 | $125.12K | 59,370 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,134 | $35.80 | $40.60K | 62,674 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −613 | $34.40 | $21.09K | 63,808 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,496 | $33.54 | $50.18K | 64,421 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,923 | $32.37 | $62.25K | 65,917 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −432 | $33.60 | $14.52K | 17,958 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −793 | $32.43 | $25.72K | 18,390 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −189 | $34.41 | $6.50K | 17,769 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −307 | $35.69 | $10.96K | 17,462 |
| Howard W. Robin President & CEO, Director | Sep 2, 2025 | Sale(10b5-1 plan) | −1,500 | $30.16 | $45.24K | 67,840 |
| Jonathan Zalevsky Chief R&D Officer | Sep 2, 2025 | Sale(10b5-1 plan) | −485 | $30.10 | $14.60K | 19,183 |
| Howard W. Robin President & CEO, Director | Aug 19, 2025 | Sale | −1,573 | $26.59 | $41.83K | 69,340 |
| Mark Andrew Wilson Chief Legal Officer | Aug 19, 2025 | Sale | −676 | $26.59 | $17.97K | 20,312 |
| Jonathan Zalevsky Chief R&D Officer | Aug 19, 2025 | Sale | −725 | $26.59 | $19.28K | 19,668 |
| Jonathan Zalevsky Chief R&D Officer | May 19, 2025 | Sale | −10,712 | $0.67 | $7.18K | 305,892 |
| Mark Andrew Wilson Chief Legal Officer | May 19, 2025 | Sale | −9,996 | $0.67 | $6.70K | 314,296 |
| Howard W. Robin President & CEO, Director | May 19, 2025 | Sale | −23,208 | $0.67 | $15.55K | 1,063,693 |
| Howard W. Robin President & CEO, Director | Feb 19, 2025 | Sale | −23,774 | $1.01 | $24.01K | 1,086,901 |
| Jonathan Zalevsky Chief R&D Officer | Feb 19, 2025 | Sale | −10,300 | $1.01 | $10.40K | 316,604 |
| Mark Andrew Wilson Chief Legal Officer | Feb 19, 2025 | Sale | −11,040 | $1.01 | $11.15K | 324,292 |
| Mark Andrew Wilson Chief Legal Officer | Dec 24, 2024 | Sale | −16,560 | $0.89 | $14.74K | 335,332 |
| Mark Andrew Wilson Chief Legal Officer | Dec 23, 2024 | Sale | −33,402 | $0.90 | $30.06K | 351,892 |
| Jonathan Zalevsky Chief R&D Officer | Dec 19, 2024 | Sale | −51,115 | $0.94 | $48.05K | 326,904 |
| Howard W. Robin President & CEO, Director | Dec 18, 2024 | Sale | −85,035 | $0.99 | $84.18K | 1,110,675 |
| Howard W. Robin President & CEO, Director | Dec 17, 2024 | Sale | −46,995 | $1.01 | $47.46K | 1,195,710 |
| Howard W. Robin President & CEO, Director | Dec 13, 2024 | Award | +410,625 | – | – | 1,242,705 |
| Mark Andrew Wilson Chief Legal Officer | Dec 13, 2024 | Award | +165,938 | – | – | 385,294 |
| Jonathan Zalevsky Chief R&D Officer | Dec 13, 2024 | Award | +135,000 | – | – | 378,019 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Howard W. Robin Officer, Director | Aug 18, 2026 | 418 | $30.09K | Aug 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Aug 18, 2026 | 186 | $13.39K | Aug 18, 2026 | Restricted Stock Vesting |
| Zalevsky Jonathan Officer | Jun 30, 2026 | 5,681 | $371.48K | Jun 30, 2026 | Restricted Stock Units |
| Howard W. Robin Officer, Director | Jun 17, 2026 | 10,000 | $602.70K | Jun 17, 2026 | Restricted Stock Vesting |
| Howard W. Robin Officer, Director | Jun 16, 2026 | 10,000 | $609.60K | Jun 16, 2026 | Restricted Stock Vesting |
| Zalevsky Jonathan Officer | Jun 15, 2026 | 5,538 | $328.85K | Jun 15, 2026 | Restricted Stock Units |
| Howard W. Robin Officer, Director | May 19, 2026 | 444 | $29.08K | May 19, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | May 19, 2026 | 199 | $13.04K | May 19, 2026 | Restricted Stock Vesting |
| Mark Andrew Wilson Former Officer | Mar 13, 2026 | 78,510 | $5.70M | Mar 13, 2026 | Option Granted - 12/13/2023 |
| Howard W. Robin Officer, Director | Feb 18, 2026 | 423 | $30.88K | Feb 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Feb 18, 2026 | 180 | $13.14K | Feb 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Jan 20, 2026 | 3,867 | $137.95K | Jan 20, 2026 | Restricted Stock Vesting |
| Howard W. Robin Officer, Director | Nov 25, 2025 | 2,207 | $129.81K | Nov 25, 2025 | Restricted Stock Vesting |
| Mark Andrew Wilson Officer | Nov 25, 2025 | 630 | $37.06K | Nov 25, 2025 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Nov 25, 2025 | 1,157 | $68.05K | Nov 25, 2025 | Restricted Stock Vesting |